Valuation: Cipher Pharmaceuticals Inc.

Market Cap 337M 238M 212M 196M 178M 22.59B 342M 2.36B 924M 11.79B 893M 874M 37.59B P/E 2026 *
11.8x
P/E 2027 * 10.9x
Enterprise Value 337M 238M 212M 196M 178M 22.59B 342M 2.36B 924M 11.79B 893M 874M 37.59B EV / Sales 2026 *
4.75x
EV / Sales 2027 * 4.14x
Free-Float
57.46%
Yield 2026 *
-
Yield 2027 * -
1 day-2.07%
1 week-2.93%
Current month-2.93%
1 month-9.68%
3 months-19.21%
6 months-27.40%
Current year-12.02%
1 week 13.25
Extreme 13.25
13.78
1 month 13.25
Extreme 13.25
14.77
Current year 13.25
Extreme 13.25
20.56
1 year 12.48
Extreme 12.48
20.56
3 years 4.3
Extreme 4.3
20.56
5 years 1.54
Extreme 1.54
20.56
10 years 0.38
Extreme 0.38
20.56
Manager TitleAgeSince
Chief Executive Officer - 29/07/2019
Director of Finance/CFO - 10/08/2024
Director of Finance/CFO - 15/08/2022
Director TitleAgeSince
Chairman - 12/06/2019
Director/Board Member 78 21/06/2023
Director/Board Member - 21/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 A TaxCompany -133,245 0.5243%
9/30/26 A TaxCompany 133,245 0.5243%
9/29/26 A Option

Director

5,000 0.0197%
Change 5-day change 1-year change 3-year change Capi.($)
-2.07%-2.93%-9.86%+195.10% 238M
+0.43%+6.59%+56.57%+107.01% 1,120B
+0.90%-2.25%+32.26%+67.33% 616B
+0.71%+3.24%+24.33%+91.20% 504B
0.00%+5.36%+34.93%+59.07% 367B
+0.52%+0.24%+72.13%+43.10% 360B
-0.05%+4.05%+19.86%+47.28% 288B
-0.95%+2.81%-1.59%+17.89% 258B
-0.35%+4.25%+44.74%+52.51% 234B
-0.75%+3.32%+27.18%+96.05% 194B
Average -0.31%+2.69%+30.06%+77.65% 394.11B
Weighted average by Cap. +0.03%+3.52%+39.42%+74.53%

Financials

2026 *2027 *
Net sales 70.85M 50.09M 44.52M 41.27M 37.55M 4.75B 71.99M 496M 194M 2.48B 188M 184M 7.91B 81.35M 57.51M 51.12M 47.38M 43.11M 5.46B 82.66M 570M 223M 2.85B 216M 211M 9.08B
Net income 27.7M 19.58M 17.41M 16.13M 14.68M 1.86B 28.14M 194M 76.03M 970M 73.49M 71.93M 3.09B 31.76M 22.45M 19.96M 18.5M 16.83M 2.13B 32.27M 222M 87.18M 1.11B 84.27M 82.47M 3.55B
Net Debt - -
Projected Income Statement - Annual - Cipher Pharmaceuticals Inc.
Logo Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
5
Date Price Change Volume
16/10/26 CA$13.25 -2.07% 12,924
15/10/26 CA$13.53 +1.35% 9,101
14/10/26 CA$13.35 -1.11% 11,548
13/10/26 CA$13.50 -1.10% 58,515
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cipher Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.25CAD
Average target price
19.45CAD
Spread / Average Target
+46.79%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cipher Pharmaceuticals Inc.